What specific FDA warning letters since 2019 have addressed nootropic supplements or ingredients by name?
Executive summary
Since 2019 the FDA has explicitly named nootropic ingredients and nootropics-focused firms in multiple warning letters—most notably actions dated February 5, 2019 that targeted sellers of piracetam, phenibut and a raft of racetam-class compounds—while allied FTC/FDA notices also called out products marketed with Alzheimer’s or other disease claims [1] [2] [3]. Public-health summaries and academic reviews collate additional ingredient-specific FDA activity (picamilon, omberacetam, vinpocetine) but the available reporting does not provide a single exhaustive list beyond the individual letters cited [4] [5].
1. Documented FDA warning letters that name nootropic ingredients by product or compound
The FDA’s warning letter to Peak Nootropics LLC (aka Advanced Nootropics), dated February 5, 2019, explicitly states that several substances offered by the firm—Adrafinil, Aniracetam, Noopept, Oxiracetam, Phenibut, Phenylpiracetam, Piracetam, and Pramiracetam—are not lawful dietary supplements and therefore are being treated as unapproved drugs in that context [1]. The Pure Nootropics LLC warning letter of the same February 5, 2019 batch similarly singles out piracetam products in its findings and was issued alongside FTC notices about disease claims [2] [6] [3]. Those FDA letters were part of coordinated enforcement in which the FTC also warned companies about Alzheimer’s-related claims and named companies including Pure Nootropics, TEK Naturals, and others [3].
2. FDA/FTC joint enforcement that named ingredient-containing products and ad claims
The FTC press release describing the February 5, 2019 action emphasizes the joint focus on supplements marketed to treat Alzheimer’s and related diseases and cites products and ingredients such as Alpha‑GPC, Lion’s Mane, and Turkey Tail mushroom powder among the claims questioned in letters to Pure Nootropics and others [3]. TEK Naturals’ FDA warning letter, contemporaneous with this enforcement, highlights “nootropic” marketing language and ties product claims to ingredients like Alpha GPC, Bacopa monnieri, Ginkgo biloba, and L‑tyrosine that the agency says were being promoted as drug-like benefits [7].
3. Additional ingredient-specific FDA attention collected by researchers and reviewers
Independent and academic reviews summarize a broader pattern of FDA action against unapproved drug ingredients appearing in nootropic products: researchers note FDA warning letters or notices involving picamilon, phenibut, omberacetam, aniracetam, and public advisories on vinpocetine for women of childbearing age [4]. Journalistic coverage and medical reporting have similarly flagged FDA letters to firms selling piracetam and phenibut and the agency’s broader outreach about illegally marketed cognitive‑enhancement products [5] [8].
4. What the records do—and do not—establish about scope and completeness
The FDA letters cited above concretely name specific compounds and companies (Peak Nootropics, Pure Nootropics, TEK Naturals) and list ingredients such as piracetam, phenibut, multiple racetams, adrafinil, and others [1] [2] [7]. Broader summaries (FTC press release, academic reviews, journalism) indicate additional ingredient names and further enforcement against multiple firms, but the available reporting here does not provide a single updated registry of every FDA letter since 2019 that references nootropic ingredients by name; therefore any assertion of completeness would exceed the sources provided [3] [4] [5].
5. Interpreting the enforcement pattern and competing perspectives
The agencies’ actions reflect two explicit concerns: companies marketing supplements with disease treatment claims (bringing them into drug territory) and the sale of unapproved pharmaceutical compounds disguised as “dietary ingredients” [3] [1]. Industry and some supplement advocates argue for consumer choice and push back against overbroad enforcement, while researchers and clinicians emphasize safety risks from unapproved drugs and mislabeled doses; these competing motives—commercial marketing, regulatory clarity, and public‑safety precaution—frame the dispute evident in the cited letters and reviews [7] [4]. The reporting here, however, does not present the firms’ full rebuttals beyond noting some companies later addressed violations (Pure Nootropics closeout letter) [9].